본문영역 바로가기
ABL Bio - medicine for A Better Life
About Us
Who We Are
History
Corporate Identity
Leadership
Contact Us
Platform & Strategies
Platform
Oncology Strategy
CNS Disease Strategy
ADC Strategy
Publications
Pipeline
Overview
ABL301
ABL503
ABL111
ABL102
ABL103
ABL104
ABL105
ABL602
ABL501
Investors & Media
Public Disclosure
Stock Information
Finance Information
Notice
News
Document & Materials
Careers
Core Competencies
Benefits
Recruitment
Recruiting Process
KOR
ENG
모바일 메뉴 보기
Investors & Media
News
Home
Investors & Media
News
[파이낸셜뉴스]
2021-04-01
ablbio
https://www.fnnews.com/news/202103311739262573
list
PREV
I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors
NEXT
I-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors
ABL Bio
About Us
Who We Are
History
Corporate Identity
Leadership
Contact Us
Platform & Strategies
Platform
Oncology Strategy
CNS Disease Strategy
ADC Strategy
Publications
Pipeline
Overview
ABL301
ABL503
ABL111
ABL102
ABL103
ABL104
ABL105
ABL602
ABL501
Investors & Media
Public Disclosure
Stock Information
Finance Information
Notice
News
Document & Materials
Careers
Core Competencies
Benefits
Recruitment
Recruiting Process
메뉴닫기